Darzalex Faspro® (daratumumab/hyaluronidase-fihj) – New indication, expanded indication
January 15, 2021 - Janssen announced the FDA approval of Darzalex Faspro (daratumumab/hyaluronidase-fihj), in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
Top